Therapeutic effects of paclitaxel-containing ultrasound contrast agents

Tartis, Michaelann; McCallan, Jennifer L.; Lum, Aaron F.H.; LaBell, Rachel; Stieger, Susanne M.; Matsunaga, Terry O.; Ferrara, Katherine W.

doi:10.1016/j.ultrasmedbio.2006.03.017

Cited by 144 publications

(104 citation statements)

References 41 publications

Supporting

Mentioning

102

Contrasting

Order By: Relevance

“…One example is the use of double emulsion techniques to obtain polymer coated oil-filled microcapsules [17]. Another technique, as described by Tartis et al [18], involves the incorporation of a drug-containing oil-phase within lipid-coated microbubbles.…”

Section: Drug Reservoirsmentioning

confidence: 99%

Crucial factors and emerging concepts in ultrasound-triggered drug delivery

Geers

Dewitte

Smedt

et al. 2012

Journal of Controlled Release

112

View full text Add to dashboard Cite

Section: Drug Reservoirsmentioning

confidence: 99%

Crucial factors and emerging concepts in ultrasound-triggered drug delivery

Geers

Dewitte

Smedt

et al. 2012

Journal of Controlled Release

112

View full text Add to dashboard Cite

“…[17][18][19] It is generally accepted that loading drugs directly into microbubbles provides greater control over drug release and deposition. However, since the microbubble shell is a thin lipid or protein membrane, its drug-loading capacity is quite limited.…”

Section: Introductionmentioning

confidence: 99%

Microbubbles coupled to methotrexate-loaded liposomes for ultrasound-mediated delivery of methotrexate across the blood–brain barrier

Xiang¹,

Liu²,

Yang³

et al. 2014

IJN

View full text Add to dashboard Cite

Methotrexate (MTX) is the single most effective agent for the treatment of primary central nervous system lymphoma. Currently, the delivery of MTX to the brain is achieved by high systemic doses, which cause severe long-term neurotoxicity, or intrathecal administration, which is highly invasive and may lead to infections or hemorrhagic complications. Acoustically active microbubbles have been developed as drug carriers for the noninvasive and brain-targeted delivery of therapeutics. However, their application is limited by their low drug-loading capacity. To overcome this limitation, we prepared microbubbles coupled to MTX-loaded liposomes using ZHIFUXIAN, a novel type of microbubbles with a superior safety profile and long circulation time. MTX-liposome-coupled microbubbles had a high drug-loading capacity of 8.91%±0.86%, and their size (2.64±0.93 μm in diameter) was suitable for intravenous injection. When used with ultrasound, they showed more potent in vitro cytotoxicity against Walker-256 cancer cells than MTX alone or MTX-loaded liposomes. When Sprague-Dawley rats were exposed to sonication, administration of these MTX-liposome-coupled microbubbles via the tail vein led to targeted disruption of the blood–brain barrier without noticeable tissue or capillary damage. High-performance liquid chromatography analysis of the brain MTX concentration showed that MTX delivery to the brain followed the order of MTX-liposome-coupled microbubbles + ultrasound (25.3±2.4 μg/g) > unmodified ZHIFUXIAN + MTX + ultrasound (18.6±2.2 μg/g) > MTX alone (6.97±0.75 μg/g) > MTX-liposome-coupled microbubbles (2.92±0.39 μg/g). Therefore, treatment with MTX-liposome-coupled microbubbles and ultrasound resulted in a significantly higher brain MTX concentration than all other treatments ( P <0.01). These results suggest that MTX-liposome-coupled microbubbles may hold great promise as new and effective therapies for primary central nervous system lymphoma and other central nervous system malignancies.

show abstract

“…Such drug-laden encapsulated microbubbles require a thick shell to increase the payload because the volume of the drug delivered by the microbubbles is relatively small compared to other means of drug delivery. A further improvement to the use of drug-laden encapsulated microbubbles is to attach a ligand that is targeted to a specific endothelial receptor (Tartis et al, 2006). This method allows the encapsulated microbubbles to adhere to the endothelial surface and thus increase local microbubble accumulation and targeted delivery.…”

Section: Introductionmentioning

confidence: 99%

Breakup of finite thickness viscous shell microbubbles by ultrasound: A simplified zero-thickness shell model

Hsiao

Chahine²

2013

The Journal of the Acoustical Society of America

View full text Add to dashboard Cite

A simplified three-dimensional (3-D) zero-thickness shell model was developed to recover the non-spherical response of thick-shelled encapsulated microbubbles subjected to ultrasound excitation. The model was validated by comparison with previously developed models and was then used to study the mechanism of bubble break-up during non-spherical deformations resulting from the presence of a nearby rigid boundary. The effects of the shell thickness and the bubble standoff distance from the solid wall on the bubble break-up were studied parametrically for a fixed insonification frequency and amplitude. A diagram of bubble shapes versus the normalized shell thickness and wall standoff was derived, and the potential bubble shapes at break-up from reentrant jets were categorized resulting in four distinct zones.

show abstract

Therapeutic effects of paclitaxel-containing ultrasound contrast agents

Cited by 144 publications

References 41 publications

Crucial factors and emerging concepts in ultrasound-triggered drug delivery

Crucial factors and emerging concepts in ultrasound-triggered drug delivery

Microbubbles coupled to methotrexate-loaded liposomes for ultrasound-mediated delivery of methotrexate across the blood–brain barrier

Breakup of finite thickness viscous shell microbubbles by ultrasound: A simplified zero-thickness shell model

Contact Info

Product

Resources

About

Therapeutic effects of paclitaxel-containing ultrasound contrast agents

Cited by 144 publications

References 41 publications

Crucial factors and emerging concepts in ultrasound-triggered drug delivery

Crucial factors and emerging concepts in ultrasound-triggered drug delivery

Microbubbles coupled to methotrexate-loaded liposomes for ultrasound-mediated delivery of methotrexate across the blood&ndash;brain barrier

Breakup of finite thickness viscous shell microbubbles by ultrasound: A simplified zero-thickness shell model

Contact Info

Product

Resources

About

Microbubbles coupled to methotrexate-loaded liposomes for ultrasound-mediated delivery of methotrexate across the blood–brain barrier